Stay updated on Adagrasib vs Docetaxel in KRAS G12C NSCLC Clinical Trial
Sign up to get notified when there's something new on the Adagrasib vs Docetaxel in KRAS G12C NSCLC Clinical Trial page.

Latest updates to the Adagrasib vs Docetaxel in KRAS G12C NSCLC Clinical Trial page
- Check5 days agoChange DetectedThe ClinicalTrials.gov footer revision changed from v3.7.2 to v3.8.0. The study record remains inaccessible and displays a 403 Forbidden error.SummaryDifference0.2%

- Check12 days agoChange DetectedA site-wide NIH banner announces updates and FAQs about terminology changes, including use of “Super Intelligence” in place of “Artificial Intelligence.”SummaryDifference1%

- Check19 days agoChange DetectedThe footer revision identifier changed from v3.7.1 to v3.7.2, while the page continued to display a 403 error.SummaryDifference0.2%

- Check26 days agoChange DetectedThe site footer revision identifier changed from v3.7.0 to v3.7.1, while the page continues to display a 403 Forbidden error.SummaryDifference0.2%

- Check47 days agoChange DetectedAccess to the study record is blocked by a 403 Forbidden page. The page now shows an error screen instead of the study details.SummaryDifference16%

- Check68 days agoChange DetectedThe study protocol document version on the page was updated from v3.6.5 to v3.6.6, indicating a newer protocol release. This reflects an administrative update to the Study Protocol and Statistical Analysis Plan documentation on the page.SummaryDifference0.0%

Stay in the know with updates to Adagrasib vs Docetaxel in KRAS G12C NSCLC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Adagrasib vs Docetaxel in KRAS G12C NSCLC Clinical Trial page.